Home > DARE Reviews > Immunoprophylaxis against respiratory...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews.

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation

Review published: 2008.

Bibliographic details: Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.  Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technology Assessment 2008; 12(36): 1-86. [PubMed: 19049692]

Quality assessment

The review concluded that prophylaxis with palivizumab was relatively safe and clinically effective in reducing the risk of serious lower respiratory tract infection caused by respiratory syncytial virus infection and in reducing the need for hospitalisation in high-risk children. This conclusion appears likely to be reliable. Full critical summary

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2013 University of York.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...